Key Developments: Thoratec Corp (THOR.OQ)

THOR.OQ on NASDAQ Stock Exchange Global Select Market

44.88USD
4:00pm EDT
Change (% chg)

$0.44 (+0.99%)
Prev Close
$44.44
Open
$44.59
Day's High
$44.92
Day's Low
$43.69
Volume
134,368
Avg. Vol
168,847
52-wk High
$46.49
52-wk Low
$22.50

Search Stocks

Latest Key Developments (Source: Significant Developments)

Thoratec Corp gives FY 2014 guidance below analysts' estimates
Tuesday, 4 Feb 2014 04:02pm EST 

Thoratec Corp:Establishes FY 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis.FY 2014 revenue of $536 million and EPS of $1.86 - Thomson Reuters I/B/E/S.  Full Article

Glancy Binkow & Goldberg LLP files class action lawsuit against Thoratec Corporation
Tuesday, 4 Feb 2014 08:04am EST 

Glancy Binkow & Goldberg LLP:It has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class comprising all purchasers of Thoratec securities between Apr. 29, 2010 and Nov. 27, 2013.Says the complaint alleges that, throughout the Class Period, defendants failed to disclose that the company's HeartMate II Left Ventricular Assist Device had risk of pump thrombosis, causing numerous fatalities.  Full Article

Thoratec Corp announces fraud class action complaint in the U.S. District Court
Tuesday, 28 Jan 2014 08:00pm EST 

Thoratec Corp:Says Robbins Arroyo LLP announces that an investor of the company has filed a federal securities fraud class action complaint in the U.S. District Court for the Northern District of California.Says the complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between Apr. 29, 2010 and Nov. 27, 2013.  Full Article

Federman & Sherwood announces filing of securities class action lawsuit against Thoratec Corporation
Tuesday, 28 Jan 2014 05:20pm EST 

Federman & Sherwood:Says a class action lawsuit was filed in the United States District Court for the Northern District of California against Thoratec Corporation.Says the complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.Says it includes allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is Apr. 29, 2010 through Nov. 27.  Full Article

Pomerantz Law Firm announces filing of class action against Thoratec Corporation and Certain Officers
Friday, 24 Jan 2014 04:10pm EST 

Pomerantz LLP:Says it has has filed a class action lawsuit against Thoratec Corporation and certain of its officers.The class action, filed in United States District Court, Northern District of California, and docketed under 14-cv-00360, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Thoratec securities between Apr. 29, 2010 and Nov. 27, 2013.Says the complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects.Says defendants failed to disclose that the Company's HeartMate II Left Ventricular Assist Device had significant risk of pump thrombosis, causing numerous fatalities. As a result of the foregoing, the company's statements were materially false and misleading at all relevant times.  Full Article

Thoratec Corp announces $200 million share repurchase
Monday, 9 Dec 2013 09:00am EST 

Thoratec Corp:Says its board of directors has authorized the repurchase of up to $200 million of the company's shares of common stock effective through the end of 2015.Says its previous share repurchase authorization will expire at the end of 2013.  Full Article

Thoratec Corp Narrows FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Wednesday, 30 Oct 2013 04:02pm EDT 

Thoratec Corp announced that for fiscal 2013, it is narrowing guidance for revenues to a range of $500 million to $505 million compared with the previous guidance range of $490 million to $510 million. The Company is increasing guidance for net income per diluted share to a range of $1.30 to $1.35 on a GAAP basis and $1.80 to $1.85 on a non-GAAP basis. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $502 million and EPS of $1.75 for fiscal 2013.  Full Article

Thoratec Corp Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Wednesday, 31 Jul 2013 04:02pm EDT 

Thoratec Corp reaffirmed prior guidance for fiscal 2013 revenues, which are expected to be in the range of $490 million to $510 million. For fiscal 2013 net income per share, the Company has adjusted its GAAP and non-GAAP guidance to account for the previously disclosed $6-7 million of recurring operating expenses (approximately $0.07 per share on an after-tax basis) associated with the development of DuraHeart II, which Thoratec recently acquired. GAAP net income per share guidance has also been adjusted to include $1.3 million of transaction-related expenses incurred through the end of the second quarter. Following these adjustments, GAAP net income per diluted share is expected to be in the range of $1.23 to $1.33, and non-GAAP net income per diluted share is expected to be in the range of $1.69 to $1.79. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $495 million for fiscal 2013.  Full Article

Search Stocks